Monica. Thanks,
the form our of of to most you of and key and is medicines of remind Bladder to means want cancer patients, it and creates physicians, expensive I very the their are is the and need and it to cancer, What new payers including sixth regulatory to work gain huge that X. in experience patient bring the cancer. as of prevalent is invaluable this to cancer market one stakeholders single most area. unmet worst, this anxious is support innovative health any approval not Slide we if worst treat, the to Vicinium. Turning the
for Thiotepa can BCG, the have through is so there important shortages of in continue helps limited very early this cancer. XXXX. expeditiously. used, know, huge option expected only need options at you as the which and it since The demonstrate been significant three we combination very to market treatment are global on unmet are ever seldomly Slide XXXXs, Vicinium X, why treatment the leaving non-muscle to approved of bring least see you founded FDA real and and And bladder Valstar was invasive as have been as only products BCG that
Again, to which kill alone. T-cells fusion unique leaving targeting just is healthy immunogenic a action. effect a is The important is most bladder remind thing cells, cell cytotoxic of that probably only Vicinium destroying through and the immediate have patient cancer the Vicinium cells the through direct tumor. protein enlist immune also selectively cancer to product. and a believe we that Slide cells, attack kills is in mechanism cancer Not on very system kill Vicinium cells how the activate and differentiated able death, patient's it a about XX generally dual Vicinium and the it while does
explain very sustainable system. In anti-tumor demonstrate and of direct patient's BCG immune a market Vicinium combination killing tolerability this dual effect the and safety activates and in that a which like and interested chemotherapy to agent able is a profile. they We thought almost doctors a with while MoA helps to believe the a effect, strong maintaining why MoA favorable we're are research,
this demonstrate with immune of also to mechanism such as we hypothesis. be inhibitors we MCI action test the and anti-PDX explains an have a why of able effect road the component activating immune anti-PDLX and trial synergistic down checkpoint The to underway may
clear you the FDA On careful are tremendous ago, step And had trials face-to-face development Vicinium program, to and been regulatory make in agency want in it XX, to you guidance. the FDA has sure alignment discuss Type working and And how I put can is years every moving meeting our this see there's a way with XXXX. We to time. again, acceleration can first that steady closely our in the the been designed with with Slide of in forward. B the context path XX see XXXX, of
Track with this Fast in the major Everything past year, correspondence other the designation end has have meetings than along this the will happened months. six face-to-face with weekly four slide we had By on of and And with to we time support, it them, like their not the the limiting. feels efforts meeting, meet be FDA, with really speaks agency. the rate partnership they to every request which their next
discussions forward on Vicinium Lastly, regulatory we for Europe. with path the EMA expect in in XXXX, start the to
much The reached please on had population and give than confirmatory patient the discussed. to XX last post-marketing We a confirmatory had for now Vicinium. been the we agency turn trial Slide on our the update So originally FDA. design broader trial will of address I'll with a with the week agreement quick meeting
is shortage, to side BCG adequate by effects, will BCG receive for least FDA discontinuation, seven whatever We treatment enroll BCG. reason, not are drug have of cetera. who able patients patients the Adequate defined had et who at doses as
partial So those doses, six our doses. may be full on patients and received who or will have study focus one to
XX% sole the know, the end manufacturer XX% BCG to you As in and can for they U.S. for the has the of shortages they at expect of said demand only XXXX. through provide BCG least
successful do have could XX% BCG qualify It access to to who include this to that patients would labeling updated expanded should of be our is simply the So our could for not patients. therefore it of this trial population leave confirmatory expectation trial. requiring XX% and be
superiority We though less The no to there of guidance agreement is control of also response, a area. the of to quality safety, This a FDA to allowing receiving and allows is to also FDA for with on compare official came and patients for us than two-arm to endpoints adequate life, study. care endpoints us with for the key standard as secondary BCG, duration efficacy complete of the demonstrate for power survival. even such this and response, the design arm in trial FDA primary
key thinking analysis reimbursement from and will payers population. a believe inform demonstrate support the of right In standard to ability about global that help to superiority expanded perspective, to data the patient this in collect we care relative
set. to are clinical we what Slide highlight our aspects I On important the of most XX, data want feel
and see we response Perhaps complete As we strong roughly cystectomy we Phase complete see non-muscle most have II because with states the and the good data the of is months to important of FDA efficacy XX% therapy cancer know, III three BCG, the efficacy that invasive Phase patients and you at cystectomy. bladder to rate avoid data in durability unresponsive response. time very with goal a
choice patients in other patient BCG, cystectomy. for Vicinium and free Vicinium, radical patients know and failed was have that on important treatment We You see These the days. only to cystectomy data average is who can XXX of are there the on these especially absence payers.
those very we mature, data at promising important. those become XX data months, still survival it's and survival early, at XX% While overall with see think as very we could
the reported important is of and and with safety patient their a biggest when this for cancer. physicians, in source tolerability of strong cancer five majority bladder vast seen where experienced to are patients profile. the grade class, than less years is for is average X% the in we and to in inhibitor Vicinium That three safety checkpoint how we to AEs prescribing especially faced AE. differentiation probably is number still have many The type what one-third mild moderate XXs the and treatment know Finally, of of treatment-related patient
global just market On of the neurologists. research, reminder Slide opportunity a the and feedback Vicinium for huge have commercial market from received we compelling XX,
opportunity on outside U.S. the guidance help also on give additional and Slides to models XX data inform We U.S. to you XX. in the the market and your
career most of a spent willing me advocate what exists all the on that virtuous patients, commercial and physicians at strongly and to are business, action. cycle for my the product the when side take jumps out is of Having payers,
a advocating So you. groups one often you're product those lucky even for in have to of launch,
from create launch three could support strong strong and profitable seen unique all have we stakeholder with far a a sustained which groups, opportunity so for And growth.
strong Slide that chain. work XX, to I want if to anticipate, the supply you our we of much putting and how just into remind you because manufacturing turn demand And global we're
based in and refined been the perfected a tried for Biologics. Our expression microbial was process manufacturing process since. and XXXXs ever on This which it's true insulin, and is system developed is for
goods of We a and we of with cost Fuji the Baxter, this are partnering issue which minimizes a and process yield with very shortages, should risk important our strong supply is manufacturers, for highly reliable obviously believe very low customers. that
there's need, with and We So every differentiated bladder significant a move a benefit highly medical commercial to summarize, pathway improving risk on bringing the day is there cancer. opportunity, believe a regulatory a with and a a we're market to saving and very well-defined unmet we profile. laser strong lives product huge patients and with forward believe we focus of
And with open on that, we'll Josh? call right are for schedule the up questions. we and
